Immune Checkpoint in Glioblastoma: Promising and Challenging

Glioblastoma (GBM) is a severe malignant brain cancer with poor overall survival. Conventional intervention remains dismal to prevent recurrence and deterioration of GBM cell. Recent years have witnessed exciting breakthroughs in novel immune strategies, especially checkpoint inhibitors, some of whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jing, Liu, Fangkun, Liu, Zhixiong, Tang, Hui, Wu, Haishan, Gong, Qianni, Chen, Jindong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422441/
https://www.ncbi.nlm.nih.gov/pubmed/28536525
http://dx.doi.org/10.3389/fphar.2017.00242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422441/
https://www.ncbi.nlm.nih.gov/pubmed/28536525
http://dx.doi.org/10.3389/fphar.2017.00242

Ejemplares similares